Planta Med 2006; 72 - P_347
DOI: 10.1055/s-2006-950147

Effects of chronic administration of Ginkgo biloba extract (EGb 761®) on levels of dopamine, noradrenaline and serotonin in the prefrontal cortex of the awake rat

J Kehr 1, 2, M Nöldner 3, T Yoshitake 1, 4
  • 1Dept. of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz väg 2, 171 77 Stockholm, Sweden
  • 2Pronexus Analytical AB, Karolinska Science Park, Fogdevreten 2a, 171 77 Stockholm, Sweden
  • 3Preclinical Reseach, Dr. Willmar Schwabe GmbH & Co. KG, Willmar-Schwabe-Str. 4, 76227 Karlsruhe, Germany
  • 4Dept. of Pharmaceutical Sciences, International University of Health and Welfare, 2600–1, Kitakanemaru, Ohtawara-shi, Tochigi 324–8501, Japan

The special Ginkgo biloba extract (EGb 761®) has been shown to exert beneficial effects in the therapy of age-related neurological disorders such as Parkinson's and Alzheimer's disease [1]. Besides neuroprotective effects, EGb 761® has been demonstrated to improve cognitive functions in animal models [2] and in clinical studies [3]. Thus, it was the aim of the present study to investigate whether EGb 761® influences monoamine levels in brain areas implicated in cognitive function, motivation and mood behaviour. For this purpose, the effect of sub-chronic (14 days) daily administration of EGb 761® on basal extracellular levels of dopamine (DA), noradrenaline (NA) and serotonin (5-HT) were monitored by microdialysis in the prefrontal cortex of awake rats. Administration of EGb 761® at a dose of 100mg/kg p.o., caused a significant increase in DA levels during 40–180min, reaching a maximum level of 163% of the control group. The extracellular levels of NA increased only by about 120% and the concentrations of 5-HT were not changed from the pre-drug levels. These findings supports previous observations suggesting that Ginkgo biloba extracts could increase monoaminergic function via inhibition of MAO activity. However, the minimal effects on NA and 5-HT concentrations indicate that EGb 761® may affect brain monoaminergic system also through other mechanisms than direct inhibition of MAO activity. These results suggest that treatment with EGb 761® can lead to increased dopaminergic function in the prefrontal cortex which may be an underlying factor to clinically observed effects on improved cognitive function.

References: 1. Andrieu, S. et al. (2003), J. Gerontol. A Biol. Sci. Med. Sci. 58: 372–377. 2. Müller, W.E., Chatterjee, S.S. (2003), Pharmacopsychiatry 36 (Suppl.1): S24. 3. Mix, J.A., Crews, W.D. (2002), Hum. Psychopharmacol. Clin. Exp. 17: 267–277.